

CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au



ASX Announcement

For immediate release

December 18, 2006

CSL Completes acquisition of CytoGam® From MedImmune

Melbourne Australia: CSL Limited announced today that its subsidiary, ZLB Behring, has completed its purchase of CytoGam® (cytomegalovirus immunoglobulin intravenous (human)) and related assets from MedImmune, Inc. CytoGam is an intravenous immunoglobulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for preventing CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of life-threatening infection occurring in solid organ transplants.

ZLB Behring paid U.S. \$120 million in cash, \$70 million of which is subject to achievement of sales milestones. ZLB Behring manufactures immunoglobulins and other plasma-derived therapies, and markets them in more than 100 countries.

The acquisition includes CytoGam and related assets, including trademarks, manufacturing contracts and government authorizations associated with the product.

For more information about CSL Limited, visit www.csl.com.au

For further information please contact:

Media Contacts

Australia and New Zealand
Dr Rachel David
Director of Public Affairs
Phone: 0401 775 779

Investor Contact

Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
E-mail: mark.dehring@csl.com.au